Lv2
122 积分 2024-02-01 加入
Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study
1个月前
已完结
Trop2 immunoPET/CT in clinical practice: facts and challenges
2个月前
已关闭
Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan
2个月前
已完结
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
2个月前
已完结
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
4个月前
已完结
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
4个月前
已完结
Envafolimab-Associated Toxic Epidermal Necrolysis
5个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
5个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
9个月前
已完结
皖公网安备34019202002308
